Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics Inc (ADMA)
:ADMA
ADMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.49 - $23.64
Previous CloseN/A
Volume407.39K
Average Volume (3M)3.61M
Market Cap
$5.22B
Enterprise Value$4.20B
Total Cash (Recent Filing)$2.93M
Total Debt (Recent Filing)$6.71M
Price to Earnings (P/E)27.0
Beta1.07
Next Earnings
May 07, 2025EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding238,563,610
10 Day Avg. Volume4,068,155
30 Day Avg. Volume3,612,075
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.03
Price to Cash Flow (P/CF)23.40
P/FCF Ratio23.40
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit19.11
Enterprise Value/Ebitda28.48
Forecast
1Y Price Target
$25.00Price Target Upside14.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
ADMA Biologics News
PremiumCompany Announcements
ADMA Biologics Earnings Call Highlights Strong Growth
PremiumCompany Announcements
ADMA Biologics Reports Strong 2024 Financial Performance---
Bulls Say, Bears Say
Bulls Say
Production CapacityIg yield enhancement approval could lead to a 20% increase in production output, boosting sales and margins.
Revenue GrowthADMA Biologics Inc has raised its 2025-2026 revenue guidance, indicating strong growth expectations.
Supply Chain StabilityThe recent long-term plasma contracts have alleviated supply concerns, supporting the growth potential for ASCENIV.
Bears Say
Board And Transaction UncertaintyConcerns on recent Board changes and transaction negotiations are considered overblown, with a positive outlook for ADMA's supply story.
Filing DelaysADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.
Guidance ConcernsKey triggers behind the sell-off were a more modest than expected 2025 guide, ambiguity on bullish implications of the enhanced supply agreements, and valuation friction.
---
Ownership Overview
3.27% Insiders
21.24% Mutual Funds
0.26% Other Institutional Investors
47.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADMA FAQ
What was ADMA Biologics Inc’s price range in the past 12 months?
ADMA Biologics Inc lowest stock price was $6.49 and its highest was $23.64 in the past 12 months.
What is ADMA Biologics Inc’s market cap?
ADMA Biologics Inc’s market cap is $5.22B.
When is ADMA Biologics Inc’s upcoming earnings report date?
ADMA Biologics Inc’s upcoming earnings report date is May 07, 2025 which is in 10 days.
How were ADMA Biologics Inc’s earnings last quarter?
ADMA Biologics Inc released its earnings results on Mar 03, 2025. The company reported $0.141 earnings per share for the quarter, missing the consensus estimate of $0.15 by -$0.009.
Is ADMA Biologics Inc overvalued?
According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued.
Does ADMA Biologics Inc pay dividends?
ADMA Biologics Inc does not currently pay dividends.
What is ADMA Biologics Inc’s EPS estimate?
ADMA Biologics Inc’s EPS estimate is 0.16.
How many shares outstanding does ADMA Biologics Inc have?
ADMA Biologics Inc has 238,563,610 shares outstanding.
What happened to ADMA Biologics Inc’s price movement after its last earnings report?
ADMA Biologics Inc reported an EPS of $0.141 in its last earnings report, missing expectations of $0.15. Following the earnings report the stock price went up 7.454%.
Which hedge fund is a major shareholder of ADMA Biologics Inc?
Currently, no hedge funds are holding shares in ADMA
---
ADMA Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (14.36% Upside)
$25.00 (14.36% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
239.44%
12-Months-Change
Fundamentals
Return on Equity
81.65%
Trailing 12-Months
Asset Growth
51.40%
Trailing 12-Months
Company Description
ADMA Biologics Inc
ADMA Biologics is a publicly traded biopharmaceutical company specializing in the development, manufacture, and commercialization of specialty plasma-derived biologics. Headquartered in the United States, ADMA focuses on treating and preventing infectious diseases in immune-compromised patients, with a portfolio that includes immune globulin products and other plasma-derived therapeutics.
---
ADMA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook for ADMA Biologics, with significant revenue growth and strategic advancements in high-titer plasma supply and ASCENIV's market potential. However, there is some uncertainty with pending FDA approval and delayed audit completion.Read More>---
ADMA Stock 12 Month Forecast
Average Price Target
$25.00
▲(14.36% Upside)
Technical Analysis
Best Analysts Covering ADMA
1 Year
1 Year Success Rate
19/25 ratings generated profit
1 Year Average Return
+82.16%
reiterated a buy rating last month
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 76.00% of your transactions generating a profit, with an average return of +82.16% per trade.
---